Other

Morehouse School of Medicine

Universidad Central Del Caribe of Bayamon

Peter Andrew Ferchmin

Khalid A El Sayed

Vesna Ana Eterovic De Ferchmin

Hector Manuel Maldonado

Vesna Ana Eterovic

Byron D Ford

Jose Wigberto Rodriguez

Eddy Oscar Rios-Olivares

Antonio Henrique Baccin Martins

Synthetic ether alkyl-lysophospholipids (APLs) provide an effective treatment for subjects suffering from cholinergic seizures. Among other uses, APLs may be used to treat the effects of epileptic seizures in particular cholinergic seizures caused by exposure to insecticides or chemical warfare nerve agent exposure. Edelfosine, an APL, has been show to be particularly effective in these areas.

Use of edelfosine and other synthetic ether alkyl-lysophospholipids (APLs) for seizures and related diseases

A method of inhibiting excitotoxicity by indirectly activating &#x3b1;4&#x3b2;2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of &#x3b1;7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate &#x3b1;4&#x3b2;2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.

Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors

A method of inhibiting excitotoxicity by indirectly activating &#x3b1;4&#x3b2;2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of &#x3b1;7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate &#x3b1;4&#x3b2;2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.

A method and composition for suppressing replication of the HIV-1 virus strains, modulating the production and liberation of inflammatory mediators; and the prevention and treatment of neurocognitive disorders. The method comprises administering to a subject an effective amount of an a macrocyclic diterpenoid, such as 4R cembranoid.

Therapeutic application of cembranoids against HIV virus replication, HIV-associated neurocognitive disorders and HIV virus-induced inflammation

A method and composition for protecting and/or treating neuroinjury are disclosed. In one aspect, the present application discloses a method for protecting and/or treating a subject from organophosphate-induced neuronal injury. The method comprises administering to a subject an effective amount of 4R cembranoid, 4S cembranoid or a cembranoid analogue. In another aspect, the application discloses neuroprotective pharmaceutical compositions for protecting and/or treating a subject from organophosphate-induced neuronal injury. A kit for protecting and treating a subject from organophosphate-induced neurodamage is also disclosed.

Growing community of inventors

San Juan, Puerto Rico

Peter Andrew Ferchmin